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Abstract
Background: Egr-1 (early growth response-1 transcription factor) has been proposed to be
involved in invasion and metastasis processes of human bladder cancer, but Egr-1 protein
expression levels in human bladder cancer have not been investigated. In the present study we
investigated the expression levels of Egr-1 protein in early stages of human bladder cancer and
correlated it to later progression.
Methods:  Expression of Egr-1 protein in human bladder cancer was examined by
immunohistochemistry, on a tissue microarray constructed from tumors from 289 patients with
non-muscle invasive urothelial bladder cancer.
Results: The frequency of tumor cells with nuclear Egr-1 immunolabelling correlated to bladder
cancer stage, grade and to later progression to muscle-invasive bladder cancer (T2-4). Stage T1
tumors exhibited significantly higher frequencies of tumor cells with nuclear Egr-1 immunolabelling
than Ta tumors (P = 0.001). Furthermore, Kaplan-Meier survival analysis showed that a high
frequency of tumor cells with nuclear Egr-1 immunolabelling was significantly associated with a
higher risk of progression to stage T2-4 (log-rank test, P = 0.035). Tumor cells with nuclear Egr-1
immunolabelling were found to localize at the tumor front in some of the tumor biopsies.
Conclusion:  The results from this study support a potential involvement of Egr-1 in the
progression from non-muscle invasive bladder cancers to muscle invasive bladder cancer.
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Background
Human bladder cancer is the forth most common malig-
nancy in men, and the tenth most common in women [1].
The majority of malignant bladder tumors are urothelial
cell carcinomas evolved from the epithelial lining of the
bladder wall (urothelium). These tumors can be further
divided into papillary, solid and carcinoma in situ (CIS)
lesions. Papillary tumors are the most common type, they
tend to grow slowly. Solid tumors are less frequent and
more aggressive and infiltrate the muscular layer of the
bladder wall. CIS is a lesion involving only the inner lin-
ing of the bladder. Bladder tumors are classified according
to the depth of invasion: non-invasive Ta, and lamina-
propria invasive but not muscle-invasive T1 tumors, and
muscle-invasive T2-4 tumors. More than 60% of the Ta
tumors recur, which makes this tumor type mainly
responsible for the high prevalence rate. About 40% of the
patients experience multiple recurrences, which has a sig-
nificant impact on the quality of life.
Studies in urothelial carcinoma cells have demonstrated
different gene expression profiles in non-muscle invasive
and muscle invasive tumors and molecular classifiers of
urothelial cell carcinoma outcome have been identified
[2]. Furthermore, different biomarker proteins have been
investigated to diagnose and prognosticate bladder can-
cers [3-6]. However, more information about different
molecular subtypes and molecular pathways of early stage
bladder tumors might ultimately facilitate prediction of
disease outcome and treatment response.
Egr-1 (early growth response factor 1, Zif268, NGFI-A,
TIS8, Krox-24) has been proposed to be involved in the
invasion and metastasis processes of human bladder can-
cer [7,8]. In both bladder and prostate cancer Egr-1 is
shown to regulate the expression of heparanase and
hyaluronidase, which are implicated in the metastatic
spread of cancer cells [8-10]. Egr-1 is a zinc finger tran-
scription factor involved in cellular responses to
mitogens, growth factors and stress stimuli. Egr-1 has also
been proposed to be an early biomarker in rat urinary
bladder cancer induced by dual-acting PPAR agonists
[11]. Egr-1 is induced by epidermal growth factor (EGF)
and has been shown to correlate to EGF receptor (EGFr)
levels in bladder tumors [7]. The EGFr is a recognized
bladder tumor marker and high levels of EGFr are associ-
ated with non-papillary, high-grade invasive tumors [12].
To our knowledge only the Egr-1 mRNA but not the pro-
tein expression levels in human bladder cancer have been
previously investigated [8]. In the present study we inves-
tigated the expression levels of Egr-1 protein in early
stages of human bladder cancer and correlated it to later
progression.
The REMARK recommendations were followed when fea-
sible [13].
Methods
Patient information
Bladder tumor biopsies were obtained with informed
written consent from the patients. The study was
approved by The Scientific Ethical Committee of the
County of Aarhus (1994/2920). All tumors selected for
this study were primary urothelial tumors, stage Ta or T1.
The patient material was collected from 1979 to 2007.
Median follow-up time was 74 months (range 1-232
months). The patient follow-up was from the first diag-
nostic resection to the most recent cystoscopy. In case of
death before progression or before a five year follow-up
without progression, the patients were excluded from the
study. The event of progression to muscle invasive bladder
cancer was verified by pathological examination. Patients
who underwent cystectomy before pathological evidence
of progression were excluded from the study. Two patients
received chemotherapy during the course of the disease
and 56 patients received bacillus Calmette-Guérin (BCG)
immunotherapy. 101 patients had concomitant CIS dur-
ing follow-up and of these 38 patients received BCG
immunotherapy.
Biological material
At the Institute of Pathology, Aarhus University Hospital,
Denmark, formalin fixed paraffin embedded urothelial
tumor blocks were selected for this study. A total of 289
patients with primary, non-muscle invasive urothelial
tumors (182 pTa, 101 pT1, 6 CIS) fulfilled the inclusion
criteria for the study; 118 tumors progressed to muscle
invasive bladder cancer (pT2-T4) during follow-up. The
remaining 171 patients were followed for at least five
years and none showed progression to muscle invasive
bladder cancer.
The original Haematoxylin-Eosin (HE) stained sections
were reviewed by an experienced uropathologist who re-
evaluated the stage and grade of each tumor blinded to
the original diagnosis. Grading was performed according
to WHO 2004 classification. The original slides for tumors
diagnosed before 1997 were not available, and conse-
quently new HE stained sections were made and evalu-
ated by the same uropathologist, who also identified the
tumor regions of each paraffin embedded bladder cancer
for the following tissue microarray construction. Tissue
samples of normal urothelium were taken from persons
with no history of bladder tumors, but who suffered from
unknown bladder pathologies that indicated bladder
biopsy.
Sections of paraffin embedded human prostate cancer
specimens (n = 3) (a kind gift from the Pathology Depart-BMC Cancer 2009, 9:385 http://www.biomedcentral.com/1471-2407/9/385
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ment, Rigshospitalet, Denmark) were used as positive
controls for Egr-1 immunolabelling, as Egr-1 is found
overexpressed in the majority of human prostate cancers
[14-17].
Tissue microarray construction
One biopsy (0.6 mm cores) from every tumor was taken
from the area marked by the uropathologist and placed in
the recipient paraffin block using a custom-made preci-
sion instrument (manual tissue microarrayer 1, Beecher
Instruments Inc., Sun Prairie, WI, USA). This was done
according to the method developed by Kononen [18].
Antibodies
Egr-1 rabbit monoclonal antibody (Cell Signaling Tech-
nology, California, USA, catalogue number 4153) was
used at 1:750 dilution.
Biotinylated secondary antibody, polyclonal goat anti-
rabbit (Dako A/S, Denmark, catalogue number E0432)
was used at 1:2000 dilution.
Immunohistochemistry
The TMA was dewaxed in xylene and rehydrated through
a graded ethanol series. Antigen retrieval was performed
by boiling for 10 minutes in 10 mM citric acid buffer, pH
6.0 in a microwave oven. Endogeneous peroxidase activity
was blocked by incubation with 3% (v/v) hydrogen per-
oxide for 10 minutes. Endogenous binding sites were
blocked using an avidin/biotin blocking kit (Vector labo-
ratories Inc., California, USA, catalogue number SP-2001)
according to the manufacturer's protocol. The TMA was
incubated with avidin for 10 minutes and washed twice in
TBST wash buffer (0.05 M Tris-HCl pH 7.6, 0.3 M NaCl
and 0.1% Tween 20) followed by biotin incubation for 10
minutes.
Immunohistochemistry for Egr-1 was done using a tyra-
mide-based catalyzed signal amplification kit, according
to the manufacturer's recommendations (Dako A/S, Den-
mark, catalogue number K1500). All incubations and
washes were done at ambient temperature. The TMA was
washed twice in TBST and blocked in protein block for 5
minutes, followed by 15 minutes incubation with anti-
Egr-1 antibody in antibody diluent (Dako A/S, Denmark,
catalogue number S3022). The TMA were washed 3 times
in TBST and underwent 5 sequential incubations with 3×
washes in TBST between each step: 15 minutes with bioti-
nylated goat anti-rabbit IgG (diluted in TBST); 15 minutes
with streptavidin-biotin complex; 15 minutes with ampli-
fication reagent; 15 minutes with streptavidin-peroxidase;
and 5 minutes with substrate chromagen solution.
Finally, the TMA were rinsed in water, counterstained with
Mayer's haematoxylin, dehydrated through ethanol into
xylene and mounted in DPX (Fisher Scientific, Loughbor-
ough, UK, catalogue number D/5319/05).
The specificity of the rabbit monoclonal antibody used in
this study has been evaluated by the use of another poly-
clonal anti-Egr-1 antibody (SC-189, Santa Cruz Biotech-
nology), and full agreement between the two was found
[11,19] and Egerod et al., 2009, submitted. Furthermore,
the observed nuclear localization of Egr-1 was in agree-
ment with that observed by others [20]. Finally, a majority
of human prostate cancer cells exhibited strong nuclear
Egr-1 immunolabelling, in agreement with the known
high expression of Egr-1 in human and mouse prostate
cancers [14-17]. No nuclear Egr-1 immunolabelling was
found in the negative prostate cancer control where the
primary antibody was omitted (figure 1 E-F). The positive
and negative control followed the same immunostaining
procedure as the TMA, with the exception for the negative
Egr-1 expression in human bladder cancer and prostate can- cer tissue Figure 1
Egr-1 expression in human bladder cancer and pros-
tate cancer tissue. Expression of Egr-1 was examined by 
immunohistochemistry in human bladder cancer tissue cores 
arranged on a tissue microarray (A-D), and in prostate can-
cer tissue (E, F). E, negative control with the primary Egr-1 
antibody omitted. Arrow, nuclear Egr-1 immunolabelling.BMC Cancer 2009, 9:385 http://www.biomedcentral.com/1471-2407/9/385
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control where the primary anti-Egr-1 antibody was omit-
ted.
Semiquantitation of Egr-1 immunolabelling
Egr-1 immunolabelling was scored (semiquantitatively)
by two persons using a double headed microscope,
according to predefined scoring criteria (see below). Scor-
ing was blinded to the course of the disease.
Egr-1 nuclear immunolabelling was scored only in tumor
cells (based on purely morphological criteria, using only
haematoxylin staining, and leaving out small lym-
phocyte-like cells). Specimens were scored as "0" when no
nuclear Egr-1 labelling was present, "1" when less than
33% of tumor cell nuclei exhibited Egr-1 immunolabel-
ling, "2" when between 33% and 67% of tumor cell nuclei
exhibited nuclear Egr-1 immunolabelling, and "3" when
over 67% of the tumor cells exhibited nuclear immunola-
belling. The intensity of the nuclear immunolabelling was
likewise scored visually in categories, "1" for weak nuclear
staining intensity, "2" for moderate nuclear staining
intensity and "3" for strong nuclear staining intensity.
The reproducibility of the Egr-1 immunolabelling was
evaluated by a second score of approximately 30 biopsies
randomly chosen from a second TMA stained on a differ-
ent day. The scores between the two TMAs were identical.
Statistics
Kruskal-Wallis and Mann Whitney tests were done using
GraphPad Prism 5 software (GraphPad Software, Inc., CA,
USA). Stata 10.0 statistical analysis software (Stata Corpo-
ration, College Station, TX, USA) was used for calculation
of Log-rank tests for equality of survival function, Kaplan-
Meier survival plots, and univariate and multivariate Cox
regression analysis. Variables with a P value < 0.01 in uni-
variate analysis were included in multivariate analysis to
identify variables with independent significance. The
assumptions of proportional hazards were verified.
Results
Of the 289 tissue cores on the TMA, some tissue cores
were missing, likely due to loss during sectioning or anti-
gen retrieval. In total 244 tissue cores (158 Ta tumors, 84
T1 tumors and 2 CIS lesions) were scored for Egr-1 protein
expression (table 1). The 2 CIS lesions represented on the
TMA were too few for statistical analysis. Only 5 tissue
cores were scored as category 3 (high Egr-1 score), and
consequently, in order to perform statistical analysis the
two Egr-1 scores of 2 and 3, were combined in one group.
Egr-1 expression levels in relation to patient and tumor 
characteristics
Egr-1 expression in 244 tumors was compared to clinical
and histopathological characteristics. The frequency and
number of Egr-1 positive tumors are listed in table 1. We
found that Egr-1 expression was correlated to tumor stage,
stage T1 tumors exhibited significantly higher levels of
Egr-1 positive tumor cells than Ta tumors (P = 0.001,
Mann Whitney test). Egr-1 expression levels were also sig-
nificantly correlated to the tumor growth patterns. The
highest Egr-1 expression was found in tumors showing
both solid and papillary growth, and lowest expression
was observed in solid tumors (P = 0.033, Kruskal-Walis
test). Finally, we found that Egr-1 expression was signifi-
cantly correlated to tumor grade. The high grade tumors
showed significantly higher levels of Egr-1 positive tumor
cells compared to low grade tumors or PUNLMP (papil-
lary urothelial neoplasm of low malignant potential) (P <
0.001, Kruskal-Walis test). There were no significant dif-
ferences in Egr-1 expression when comparing sex or tumor
size.
Correlation between Egr-1 expression levels and 
progression free survival
Kaplan-Meier survival statistics showed that tumors with
high percentages of Egr-1 positive tumor nuclei had a sig-
nificantly higher risk of progression to stage T2-4 (log-
rank test, P = 0.035, figure 2). The survival curves pre-
sented in figure 2 suggest that patients with lack of Egr-1
protein in the cancer cells constitute a seperat subpopula-
tion with a more favourable prognosis than patients with
either low, moderate or high Egr-1 protein expression.
Indeed separating the patients into only two groups (no
Egr-1 versus Egr-1 protein) resulted in significant different
prognosis for the two groups (P = 0.014) (not shown).
The associations between patient age, sex, stage, grade,
tumor size, treatment, concomitant CIS, tumor type and
Egr-1 protein expression with progression to T2-T4 inva-
sive tumors were tested by univariate Cox regression anal-
ysis (table 2). In the univariate analysis Egr-1, patient age,
tumor type, tumor stage and tumor grade showed a signif-
icant association with progression to T2-T4. Risk factors
that were significant (P < 0.01) in the univariate analysis
were included in the multivariate analysis. However in the
multivariate analysis, Egr-1 expression levels did not
prove to be an independent variable for predicting pro-
gression to T2-T4 (table 2).
Egr-1 expression localization and intensity of 
immunolabelling
In some cases, tumor cells with nuclear Egr-1 immunola-
belling were found to localize predominantly at the tumor
front, i.e. at the border between the bladder tumor and the
normal bladder stromal cells (figure 1D). The apparent
preponderance of Egr-1 labelling at the tumor front was
not found in all specimens. In some cases, tumor cells
with nuclear Egr-1 immunolabelling were also found rel-
atively evenly distributed throughout the tumor tissue asBMC Cancer 2009, 9:385 http://www.biomedcentral.com/1471-2407/9/385
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illustrated in figure 1 A-C. No statistically significant dif-
ference was found in the intensity of Egr-1 nuclear immu-
nolabeling between the Ta tumors and T1 tumors (P =
0.124, not shown).
Egr-1 expression in non-tumorigenic bladder tissue
The urothelium in three bladder specimens from non-
tumorigenic human bladder tissue were examined for Egr-
1 immunolabelling. No Egr-1 positive nuclei were found
in the urothelium (not shown).
Discussion
A role for Egr-1 in human bladder cancer progression
would be expected from the fact that Egr-1 regulates
heparanase and HYAL-1 hyaluronidase expression in
human bladder cancer cells [8,9]. In bladder cancer cells
upregulation of heparanase expression is shown to occur
in a stepwise manner where hypomethylation of the
heparanase gene promoter facilitates Egr-1 binding,
which is shown to directly regulate the heparanase expres-
sion [8]. Heparanase plays a critical role in the degrada-
tion of the extracellular matrix and the basement
membranes and overexpression is correlated with
increased metastatic potential and thereby worse progno-
sis [21]. Heparanase expression has been found upregu-
lated in gastric, pancreatic, melanoma, prostate and
bladder cancers [21-25].
Table 1: Patient and tumor characteristics
Characteristics Numbera Number Egr-1 positive biopsies Percent Egr-1 positive biopsies P
All patients 244
Sex
Male 193 109 56.2 0.882d
Women 51 28 54.9
Tumor size
< 3 cm 153 81 52.9 0.282d
> 3 cm 63 40 63.5
Tumor type
Papillary 213 118 55.4 0.033e
Solid 16 7 43.8
Mixed 13 12 92.3
Tumor stage
Ta 158 79 50.0 0.001d
T1 84 58 69.0
CISb 20
Histological grade
PUNLMPc + Low grade 158 78 49.4 < 0.001d
High grade 83 58 69.9
aOf the 289 biopsies on the TMA, analysis was only possible of 244 biopsies
bExcluded from analysis (too few represented)
cPapillary urothelial neoplasm of low malignant potential
dMann Whitney test
eKruskal-Wallis test.BMC Cancer 2009, 9:385 http://www.biomedcentral.com/1471-2407/9/385
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Also the HYAL-1 hyaluronidase expression in bladder can-
cer has been suggested to be regulated by binding of Egr-
1 to the methylated promoter of HYAL-1 hyaluronidase
[9].
Hyaluronidase is a highly sensitive and specific marker for
high-grade bladder cancer and elevated levels have also
been shown in prostate, head, neck and breast cancers and
in malignant glioma [9,26-29]. Hyaluronidases degrades
hyaluronic acid, which also serves as a tumor marker and
promotes metastasis [4,6,29,30].
While heparanase expression was not found in normal
bladder tissue, low HYAL-1 hyaluronidase expression was
found in normal bladder tissue compared to tumor tissue
[8,9]. In the present study, we did not find Egr-1 expres-
sion in the three normal human bladder specimens exam-
ined (not shown), further supporting a possible role for
Egr-1 in human bladder carcinogenesis. Likewise, we pre-
viously found that normal rat bladder urothelium
expresses no or low levels of Egr-1 [11,19] and Egerod et
al., 2009, submitted.
Egr-1 has been shown to regulate the transformation to
invasive carcinoma in prostate cancer tumorigenesis,
where Egr-1 deficient mice display impaired tumorigene-
sis [14]. Also inhibition of Egr-1 by antisense oligonucle-
otides reversed transformation of prostate cancer cells in
vitro and in vivo [31].
Because bladder and prostate cancer co-occurs in some
patients, it has been suggested that these 2 cancer forms
share a common molecular mechanism [32]. The mecha-
nism behind Egr-1 expression in both bladder and pros-
tate cancer are unexplored, but potent inducers of Egr-1
could be stimuli present in tumors in vivo such as hypoxia,
growth factors and inflammation. One of the clinical
implications of our study is that it indirectly supports that
the molecular mechanisms underlying bladder and pros-
tate cancer may be similar. Another implication of our
study is that it opens new avenues for determining the
molecular mechanisms underlying bladder cancer. By per-
forming chromatin immunoprecipitation experiments
with Egr-1 antibodies, it may be feasible to determine
genes regulated by Egr-1 in invasive human bladder
tumor specimens. This would have long-term clinical
implications for diagnosis as well as treatment of bladder
cancer.
Our study strengthens the role of Egr-1 as a mediator of
transformation to invasive bladder cancers. In the univar-
iate analysis Egr-1 was significantly associated with pro-
Kaplan-Meier plot Figure 2
Kaplan-Meier plot. Kaplan-Meier survival curve illustrating correlation between Egr-1 score (frequency of Egr-1 positive can-
cer cell nuclei in tumor mass) and progression to stage T2-T4 bladder cancer. Information from 244 patients was included. P = 
0.035, log rank test. Total number of events were 96, with 33 events in Egr-1 negative, 44 events in low Egr-1 and 19 invents in 
moderate/high Egr-1.BMC Cancer 2009, 9:385 http://www.biomedcentral.com/1471-2407/9/385
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gression to T2-T4; however this was not the case in the
multivariante analysis. Therefore Egr-1 cannot be consid-
ered an independent marker for progression to T2-T4.
Nevertheless, in our study, Egr-1 was still found associated
with tumor stage, tumor grade and progression to invasive
tumors. Furthermore, we know from previous gene
expression studies that Egr-1 is over expressed in muscle
invasive tumors. This also emphasizes that Egr-1 may play
a role in tumor progression.
CIS is often associated with a high risk of disease progres-
sion. Unfortunately, this study included very few CIS
lesions, and consequently further work is needed to exam-
ine to what extent Egr-1 is expressed in CIS lesions.
Conclusion
Our study supports a role of Egr-1 in the early steps of
human bladder carcinogenesis, with progression from
non-muscle invasive tumors to muscle invasive cancers,
and emphasizes the need for more comprehensive studies
to explore the involvement of Egr-1 in human bladder
cancer.
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